The Global Shift Towards Plant Medicine... Are We Paying Attention?

The other day I found myself thinking about something that I don't think enough people are talking about.

For years we've argued about whether cannabis should be legal. Then the conversation moved to psychedelics. Now, while people are still having those same old arguments, something else is happening quietly in the background.

Countries are investing billions into research. Universities are publishing more studies every year. Pharmaceutical companies are buying psychedelic companies for billions of dollars because they clearly believe this is going somewhere. Eli Lilly didn't spend up to $3.8 billion buying AtaiBeckley because someone thought it would make a good headline. They did it because they see a future in this space.

That got me thinking...

If some countries are investing in this, creating jobs around it, attracting scientists, clinicians and businesses, what does that eventually mean for the people living there? What does it mean for the economy? What does it mean for healthcare?

What does it mean for the people who have access to treatments that simply don't exist somewhere else?

Then I started thinking about businesses.

Imagine you're running a company in a country that still refuses to even have the conversation. Meanwhile, another company on the other side of the world is paying attention to the latest research into the endocannabinoid system, psychedelic-assisted therapies, mental health and nervous system regulation.

They're learning. They're adapting. They're understanding their workforce differently because science is moving and they're moving with it.

Wouldn't you be wondering whether you're falling behind?

I'm not even talking about taking cannabis anymore. I'm not talking about taking psilocybin or ibogaine either. To be honest, I think that conversation is becoming less interesting by the day.

The question I'm interested in is whether we're prepared to ignore where the science is going.

History has a funny way of repeating itself. The people who dismiss something at the beginning often end up trying to catch up later. We've seen it with technology, we've seen it with renewable energy, we've seen it with artificial intelligence, and I can't help wondering whether we're watching the same thing happen with plant medicines.

Maybe in ten years we'll look back and wonder why we spent so much time arguing about whether we should research these medicines instead of asking how we could research them responsibly.

The truth is, there are people alive today who have legal access to treatments that people in another country can only read about online. Some have access to prescribed medical cannabis. Others can take part in regulated psychedelic programmes. They're contributing to research that could shape the future of medicine, while someone somewhere else is still being told that the conversation shouldn't even exist.

I don't know about you, but if there are people living in another country who genuinely have access to treatments that may improve quality of life, help people recover from difficult conditions, or simply allow researchers to understand the human brain better, I'd want to know why.

Not because I think every plant is for everybody.

Not because I think everyone should rush out looking for a prescription.

I'd want to know because I don't like the idea of being left behind.

If another country is building the future of healthcare, another business is learning how to support its workforce better, and another generation is growing up with access to treatments that my country refuses to even discuss, then surely that's something worth paying attention to.

To me, this isn't really about cannabis anymore.

It's about whether we're prepared to learn.

Or whether we're happy waiting for everyone else to show us what we've been missing.